IGC Pharma (IGC) Current Assets (2011 - 2026)

IGC Pharma (IGC) has 16 years of Current Assets data on file, last reported at $1.1 million in Q1 2026.

• Current Assets for Q1 2026 came in at $1.1 million, down 60.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 60.39% YoY), and the FY2026 annual result was $1.1 million, down 60.39% from the prior year.
• Current Assets declined to $1.1 million in Q1 2026 per IGC's latest filing, from $1.8 million in the prior quarter.
• Over five years, Current Assets peaked at $15.1 million in Q1 2022 and troughed at $1.1 million in Q1 2026.
• A 5-year average of $5.6 million and a median of $4.2 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets tumbled 61.7% in 2023, then declined 13.21% in 2024.
• A 5-year view of Current Assets shows it stood at $9.4 million in 2022, then plunged by 61.7% to $3.6 million in 2023, then retreated by 14.85% to $3.1 million in 2024, then sank by 41.33% to $1.8 million in 2025, then slumped by 35.92% to $1.1 million in 2026.
• Business Quant data shows IGC's Current Assets at $1.1 million in Q1 2026, $1.8 million in Q4 2025, and $2.0 million in Q3 2025.